Cargando…

Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring

AIMS/INTRODUCTION: The combination therapy of dipeptidyl‐peptidase (DPP)‐4 inhibitor and α‐glucosidase inhibitors (α‐GIs) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurozumi, Akira, Okada, Yosuke, Mori, Hiroko, Arao, Tadashi, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020235/
https://www.ncbi.nlm.nih.gov/pubmed/24843685
http://dx.doi.org/10.1111/jdi.12059
_version_ 1782316035073900544
author Kurozumi, Akira
Okada, Yosuke
Mori, Hiroko
Arao, Tadashi
Tanaka, Yoshiya
author_facet Kurozumi, Akira
Okada, Yosuke
Mori, Hiroko
Arao, Tadashi
Tanaka, Yoshiya
author_sort Kurozumi, Akira
collection PubMed
description AIMS/INTRODUCTION: The combination therapy of dipeptidyl‐peptidase (DPP)‐4 inhibitor and α‐glucosidase inhibitors (α‐GIs) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used in combination with DPP‐4 inhibitor by using continuous glucose monitoring (CGM). MATERIALS AND METHODS: In a randomized cross‐over study, 16 patients with type 2 diabetes who presented with postprandial hyperglycemia despite alogliptin (25 mg) were treated with voglibose (0.9 mg) or miglitol (150 mg). We measured standard deviation (SD); mean amplitude of glycemic excursions (MAGE), and mean, minimum and maximum glucose measured by CGM during three phases (alogliptin monotherapy, dual therapy of alogliptin and voglibose, and dual therapy of alogliptin and miglitol). The primary outcome measure was SD between α‐GIs. RESULTS: SD was significantly improved by the addition of either voglibose (18.9 ± 10.1) or miglitol (19.6 ± 8.2) to alogliptin monotherapy (36.2 ± 8.7). MAGE improved significantly with the addition of either voglibose (57.5 ± 26.1, P < 0.01) or miglitol (64.6 ± 26.2, P < 0.01) to alogliptin monotherapy (101.5 ± 21.5). There was no significant difference in glucose fluctuation between α‐GIs. There were no differences between two groups in mean (132.6 ± 21.4 and 138.7 ± 25.4) and maximum (184.3 ± 48.7 and 191.9 ± 38.3). The minimum glucose under alogliptin plus voglibose (94.9 ± 20.2) was significantly lower than that under alogliptin and miglitol (105.3 ± 21.0). CONCLUSIONS: Glucose fluctuation was improved by the addition of voglibose or miglitol to alogliptin. Glucose fluctuations and postprandial hyperglycemia were similar between α‐GIs. This trial was registered with the University Hospital Medical Information Network (no. UMIN R000010028).
format Online
Article
Text
id pubmed-4020235
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Wiley-Blackwell
record_format MEDLINE/PubMed
spelling pubmed-40202352014-05-19 Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring Kurozumi, Akira Okada, Yosuke Mori, Hiroko Arao, Tadashi Tanaka, Yoshiya J Diabetes Investig Articles AIMS/INTRODUCTION: The combination therapy of dipeptidyl‐peptidase (DPP)‐4 inhibitor and α‐glucosidase inhibitors (α‐GIs) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used in combination with DPP‐4 inhibitor by using continuous glucose monitoring (CGM). MATERIALS AND METHODS: In a randomized cross‐over study, 16 patients with type 2 diabetes who presented with postprandial hyperglycemia despite alogliptin (25 mg) were treated with voglibose (0.9 mg) or miglitol (150 mg). We measured standard deviation (SD); mean amplitude of glycemic excursions (MAGE), and mean, minimum and maximum glucose measured by CGM during three phases (alogliptin monotherapy, dual therapy of alogliptin and voglibose, and dual therapy of alogliptin and miglitol). The primary outcome measure was SD between α‐GIs. RESULTS: SD was significantly improved by the addition of either voglibose (18.9 ± 10.1) or miglitol (19.6 ± 8.2) to alogliptin monotherapy (36.2 ± 8.7). MAGE improved significantly with the addition of either voglibose (57.5 ± 26.1, P < 0.01) or miglitol (64.6 ± 26.2, P < 0.01) to alogliptin monotherapy (101.5 ± 21.5). There was no significant difference in glucose fluctuation between α‐GIs. There were no differences between two groups in mean (132.6 ± 21.4 and 138.7 ± 25.4) and maximum (184.3 ± 48.7 and 191.9 ± 38.3). The minimum glucose under alogliptin plus voglibose (94.9 ± 20.2) was significantly lower than that under alogliptin and miglitol (105.3 ± 21.0). CONCLUSIONS: Glucose fluctuation was improved by the addition of voglibose or miglitol to alogliptin. Glucose fluctuations and postprandial hyperglycemia were similar between α‐GIs. This trial was registered with the University Hospital Medical Information Network (no. UMIN R000010028). Wiley-Blackwell 2013-03-07 2013-07-08 /pmc/articles/PMC4020235/ /pubmed/24843685 http://dx.doi.org/10.1111/jdi.12059 Text en Copyright © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd
spellingShingle Articles
Kurozumi, Akira
Okada, Yosuke
Mori, Hiroko
Arao, Tadashi
Tanaka, Yoshiya
Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
title Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
title_full Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
title_fullStr Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
title_full_unstemmed Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
title_short Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
title_sort efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020235/
https://www.ncbi.nlm.nih.gov/pubmed/24843685
http://dx.doi.org/10.1111/jdi.12059
work_keys_str_mv AT kurozumiakira efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring
AT okadayosuke efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring
AT morihiroko efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring
AT araotadashi efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring
AT tanakayoshiya efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring